Truist Securities maintains ArriVent BioPharma at Buy, raises price target to $24 from $21
Truist Securities maintained its Buy rating on ArriVent BioPharma and increased its price target to $24 from $21, representing a 14.3% increase. This new target suggests a 69.5% upside from the stock's Nov 9 close of $14.16. Other recent analyst price targets for the company range from $29 to $30.
How this was made

The 30-second read
Why it matters
The price‑target increase suggests a potential upside of roughly 70% from current levels, but without a catalyst the effect may be muted.
Market read
Analyst target adjustments are modest drivers of price movement for small caps; traders may watch for any follow‑up catalyst.
What to watch
No recent clinical data released; the raise is purely analyst opinion.
Background
ArriVent BioPharma is a micro‑cap biotech listed on NASDAQ. Analyst coverage is limited, making target changes notable for traders.
Market effects
May slightly lift sentiment in the small‑cap biotech sector.
Limited to U.S. biotech investors.
Minimal
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystTruist Securities
Equity research firm that issued the target raise.
- CompanyArriVent BioPharma
Biopharmaceutical company focused on oncology therapies.
